FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297819854> ?p ?o ?g. }

• W4297819854 endingPage "910" @default.
• W4297819854 startingPage "902" @default.
• W4297819854 abstract "BACKGROUND A prospective, randomized Phase III trial was performed to determine whether, compared with gemcitabine (GEM) alone, the addition of cisplatin (CDDP) to GEM was able to improve the time to disease progression and the clinical benefit rate in patients with advanced pancreatic adenocarcinoma. The objective response rate, overall survival rate, and toxicity patterns of patients in the two treatment arms were evaluated as secondary end points. METHODS Patients with measurable, locally advanced and/or metastatic pancreatic adenocarcinoma were randomized to receive GEM (Arm A) or a combination of GEM and CDDP (Arm B). In Arm A, a dose of 1000 mg/m2 GEM per week was administered for 7 consecutive weeks, and, after a 2-week rest, treatment was resumed on Days 1, 8, and 15 of a 28-day cycle for 2 cycles. In Arm B, CDDP was given at a dose of 25 mg/m2 per week 1 hour before GEM at the same dose that was used in Arm A. On Day 22, only GEM was administered. Patients were restaged after the first 7 weeks of therapy and then again after the other 2 cycles. RESULTS A total of 107 patients entered the trial: Fifty-four patients were randomized to Arm A, and 53 patients were randomized to Arm B. The median time to disease progression was 8 weeks in Arm A and 20 weeks in Arm B; this difference was statistically significant (P = 0.048). In Arm A, one complete response and four partial responses were recorded on the basis of an intent-to-treat analysis, with an overall response rate of 9.2% (95% confidence interval [95%CI], 3–20%). In Arm B, there were no complete responses, whereas 14 partial responses were achieved, with an overall response rate of 26.4% (95%CI, 15–40%). This difference in the overall response rates was statistically significant (P = 0.02). The tumor growth control rate (i.e., total number of patients who achieved complete responses, partial responses, and stable disease) was 42.6% (95%CI, 29–57%) in Arm A and 56.6% (95%CI, 42–70%) in Arm B. A clinical benefit was observed in 21 of 43 patients (49%) in Arm A and in 20 of 38 patients (52.6%) in Arm B without any significant difference. The median overall survival was 20 weeks for patients in Arm A and 30 weeks for patients in Arm B (P = 0.43). Toxicity was mild in both treatment arms, with no significant differences between the two groups except for the statistically higher incidence of Grade 1–2 asthenia in Arm B (P = 0.046). CONCLUSIONS The addition of CDDP to GEM significantly improved the median time to disease progression and the overall response rate compared with GEM alone. The clinical benefit rate was similar in both arms, whereas the median overall survival rate was more favorable for Arm B, although the difference did not attain statistical significance. The authors conclude that the combination of CDDP and GEM currently may be considered as an optimal treatment for patients with locally advanced and/or metastatic adenocarcinoma of the pancreas. Cancer 2002;94:902–10. © 2002 American Cancer Society. DOI 10.1002/cncr.10323" @default.
• W4297819854 created "2022-10-01" @default.
• W4297819854 creator A5013748999 @default.
• W4297819854 creator A5021225962 @default.
• W4297819854 creator A5023126910 @default.
• W4297819854 creator A5046559582 @default.
• W4297819854 creator A5046785006 @default.
• W4297819854 creator A5062643447 @default.
• W4297819854 creator A5071630640 @default.
• W4297819854 creator A5077099724 @default.
• W4297819854 creator A5085152226 @default.
• W4297819854 creator A5086693219 @default.
• W4297819854 date "2002-02-15" @default.
• W4297819854 modified "2023-10-18" @default.
• W4297819854 title "Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma" @default.
• W4297819854 cites W1855374361 @default.
• W4297819854 cites W1867318780 @default.
• W4297819854 cites W1931508686 @default.
• W4297819854 cites W1959900711 @default.
• W4297819854 cites W1968837173 @default.
• W4297819854 cites W1971150016 @default.
• W4297819854 cites W1978876237 @default.
• W4297819854 cites W1979374714 @default.
• W4297819854 cites W1981617190 @default.
• W4297819854 cites W1994410190 @default.
• W4297819854 cites W1999465727 @default.
• W4297819854 cites W2003618771 @default.
• W4297819854 cites W2010833449 @default.
• W4297819854 cites W2018473224 @default.
• W4297819854 cites W2024210946 @default.
• W4297819854 cites W2027752561 @default.
• W4297819854 cites W2044313019 @default.
• W4297819854 cites W2046772809 @default.
• W4297819854 cites W2049969048 @default.
• W4297819854 cites W2084562398 @default.
• W4297819854 cites W2128889451 @default.
• W4297819854 cites W2136664234 @default.
• W4297819854 cites W2146014573 @default.
• W4297819854 cites W2151767652 @default.
• W4297819854 cites W2169278727 @default.
• W4297819854 cites W2289397400 @default.
• W4297819854 cites W4244373493 @default.
• W4297819854 doi "https://doi.org/10.1002/cncr.10323" @default.
• W4297819854 hasPublicationYear "2002" @default.
• W4297819854 type Work @default.
• W4297819854 citedByCount "244" @default.
• W4297819854 countsByYear W42978198542012 @default.
• W4297819854 countsByYear W42978198542013 @default.
• W4297819854 countsByYear W42978198542014 @default.
• W4297819854 countsByYear W42978198542015 @default.
• W4297819854 countsByYear W42978198542016 @default.
• W4297819854 countsByYear W42978198542017 @default.
• W4297819854 countsByYear W42978198542018 @default.
• W4297819854 countsByYear W42978198542019 @default.
• W4297819854 countsByYear W42978198542020 @default.
• W4297819854 countsByYear W42978198542021 @default.
• W4297819854 countsByYear W42978198542022 @default.
• W4297819854 countsByYear W42978198542023 @default.
• W4297819854 crossrefType "journal-article" @default.
• W4297819854 hasAuthorship W4297819854A5013748999 @default.
• W4297819854 hasAuthorship W4297819854A5021225962 @default.
• W4297819854 hasAuthorship W4297819854A5023126910 @default.
• W4297819854 hasAuthorship W4297819854A5046559582 @default.
• W4297819854 hasAuthorship W4297819854A5046785006 @default.
• W4297819854 hasAuthorship W4297819854A5062643447 @default.
• W4297819854 hasAuthorship W4297819854A5071630640 @default.
• W4297819854 hasAuthorship W4297819854A5077099724 @default.
• W4297819854 hasAuthorship W4297819854A5085152226 @default.
• W4297819854 hasAuthorship W4297819854A5086693219 @default.
• W4297819854 hasBestOaLocation W42978198541 @default.
• W4297819854 hasConcept C121608353 @default.
• W4297819854 hasConcept C126322002 @default.
• W4297819854 hasConcept C126894567 @default.
• W4297819854 hasConcept C141071460 @default.
• W4297819854 hasConcept C146357865 @default.
• W4297819854 hasConcept C151730666 @default.
• W4297819854 hasConcept C168563851 @default.
• W4297819854 hasConcept C2776694085 @default.
• W4297819854 hasConcept C2778239845 @default.
• W4297819854 hasConcept C2778822529 @default.
• W4297819854 hasConcept C2780210213 @default.
• W4297819854 hasConcept C2780258809 @default.
• W4297819854 hasConcept C2781182431 @default.
• W4297819854 hasConcept C29730261 @default.
• W4297819854 hasConcept C71924100 @default.
• W4297819854 hasConcept C86803240 @default.
• W4297819854 hasConceptScore W4297819854C121608353 @default.
• W4297819854 hasConceptScore W4297819854C126322002 @default.
• W4297819854 hasConceptScore W4297819854C126894567 @default.
• W4297819854 hasConceptScore W4297819854C141071460 @default.
• W4297819854 hasConceptScore W4297819854C146357865 @default.
• W4297819854 hasConceptScore W4297819854C151730666 @default.
• W4297819854 hasConceptScore W4297819854C168563851 @default.
• W4297819854 hasConceptScore W4297819854C2776694085 @default.
• W4297819854 hasConceptScore W4297819854C2778239845 @default.
• W4297819854 hasConceptScore W4297819854C2778822529 @default.
• W4297819854 hasConceptScore W4297819854C2780210213 @default.
• W4297819854 hasConceptScore W4297819854C2780258809 @default.

• next